Review article · 2025
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis
Annals of Internal Medicine, 179(2), 216–229 · Published 8 December 2025 · DOI 10.7326/annals-25-02237
In brief
“Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis” is a 2025 review article by Albert Ko and 14 co-authors, published in Annals of Internal Medicine. OpenAlex counts 55 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 55
- Most cited in
- 2026 (55)
- Field-weighted impact
- 5.10
- References
- 79
- Authors
- 15
Abstract
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for type 2 diabetes mellitus (T2DM) and overweight or obesity, but their association with cancer is unclear. PURPOSE: To investigate the risk for obesity-related cancer associated with GLP-1RAs. DATA SOURCES: PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials from inception to… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., Hsia, Y. P., Chiang, C., Xu, X., Lin, S., & Chiang, C. (2025). Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 179(2), 216–229. https://doi.org/10.7326/annals-25-02237
MLA 9
Ko, Albert, et al. “Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis.” Annals of Internal Medicine, vol. 179, no. 2, 2025, pp. 216–229. https://doi.org/10.7326/annals-25-02237.
Chicago
Ko, Albert, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, et al. 2025. “Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis.” Annals of Internal Medicine 179 (2): 216–229. https://doi.org/10.7326/annals-25-02237.
Harvard
Ko, A. et al. (2025) ‘Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis’, Annals of Internal Medicine, 179(2), pp. 216–229. doi:10.7326/annals-25-02237.
IEEE
A. Ko et al., “Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis,” Annals of Internal Medicine, vol. 179, no. 2, pp. 216–229, 2025, doi: 10.7326/annals-25-02237.
BibTeX
@article{ko2025risk,
title = {{Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis}},
author = {Ko, Albert and Chang, Yu-Cheng and Bahar, Furkan and Wang, Tsu Hsien and Xanthavanij, Nutchapon and Yu, Chun-Chiao and Hsieh, Rebecca Jen-Ling and See, Xin Ya and Lo, Shao‐Wei and Song, Junmin and Hsia, Yuan Ping and Chiang, Cho‐Hung and Xu, Xiaocao and Lin, Shuwen and Chiang, Cho‐Han},
journal = {Annals of Internal Medicine},
year = {2025},
volume = {179},
number = {2},
pages = {216--229},
doi = {10.7326/annals-25-02237},
url = {https://doi.org/10.7326/annals-25-02237}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- GLP-1 receptor agonists
- GIP/GLP-1 receptor agonist
- cancer risk
- obesity-related cancer
- type 2 diabetes
- thyroid cancer
- pancreatic cancer
- breast cancer
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., Hsia, Y. P., Chiang, C., Xu, X., Lin, S., & Chiang, C. (2025). Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 179(2), 216–229. https://doi.org/10.7326/annals-25-02237
How many times has this paper been cited?
55 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Albert Ko, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, Xin Ya See, Shao‐Wei Lo, Junmin Song, Yuan Ping Hsia, Cho‐Hung Chiang and 3 more.
What is the DOI of this paper?
10.7326/annals-25-02237, permanently at https://doi.org/10.7326/annals-25-02237. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.